Diabetes
Conditions
Interventions
Notification letter plus medical consultation by public health nurse or registered dietician using telephone
Notification letter
Sponsors
Gifu University, Tokai National Higher Education and Research System
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Insured patients never having hospital/clinical visits and those discontinuing hospital/clinical visits who meet following inclusion criteria: 1) Never having hospital/clinical visits - With diabetes nephropathy stage 1 or 2 (see below for definition) - Without no diabetes treatment in interview at medical health checkup - Without diabetes disease code in health insurance claims (FY2018 to FY2021) - Without diabetes drug code in health insurance claims (FY2018 to FY2021) 2) Patients discontinuing hospital/clinical visits 2-1) Patients who meet following all criteria with medical health checkup in 2020: - With diabetes nephropathy stage 1 or 2 (see below for definition) - Without no diabetes treatment in interview at medical health checkup - Meeting following all criteria: # Without diabetes disease code in health insurance claims (January to March, 2022) # Without diabetes drug code in health insurance claims (January to March, 2022) # Meeting one of following criteria: $ With diabetes disease code in health insurance claims (April 2018 to December 2021) $ Patients with diabetes drug code in health insurance claims (April 2018 to December 2021) 2-2) Patients who meet following all criteria without medical health checkup in 2020: # Without diabetes disease code in health insurance claims (January to March, 2022) # Without diabetes drug code in health insurance claims (January to March, 2022) # Meeting one of following criteria: $ With diabetes disease code in health insurance claims (April 2018 to December 2021) $ With diabetes drug code in health insurance claims (April 2018 to December 2021) (Definition of Patients with diabetes nephropathy stage 1 or 2) Patients who meet following all criteria: #HbA1c 6.5% or above; or fasting plasma glucose 126 mg/dL or above (casual plasma glucose 200 mg/dL or above) #urinary protein (-) or (+/-)
Exclusion criteria
Exclusion criteria: 1) Insured patients never having hospital/clinical visits and those discontinuing hospital/clinical visits who are suspected to have diabetes nephropathy stage 3 or above (Definition of Patients with diabetes nephropathy stage 1 or 2) Patients who meet following all criteria: # HbA1c 6.5% or above; or fasting plasma glucose 126 mg/dL or above (casual plasma glucose 200 mg/dL or above) # Albuminuria (300 mg/gCre or above), proteinuria (0.5g/gCre or above) or eGFR 30 ml/min/1.73m2 or below 2) Insured patients who show their intention not to participate the current study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of hospital/clinic visits for diabetes 100X[the number of insured patients who visited hospital/clinic visits for diabetes (ICD-10 E10-E14) after medical consultation*] divided by [the number of insured patients who received medical consultation] *, medical consultation (i.e., notification letter, telephone or home visit) conducted at last | — |
Secondary
| Measure | Time frame |
|---|---|
| the rate of hospital/clinic continuous visits for diabetes 100X[the number of insured patients who visited hospital/clinic visits for diabetes (ICD-10 E10-E14) twice or more after medical consultation*] divided by [the number of insured patients who received medical consultation] *, medical consultation (i.e., notification letter, telephone or home visit) conducted at last | — |
Countries
Japan
Contacts
Public ContactTakehiro Kato
Gifu University, Tokai National Higher Education and Research System Department of Diabetes, Endocrinology and Metabolism, Graduate School of Medicine
Outcome results
None listed